relates: Candidate name: Sushmi Dey | New Delhi March 30‚ 2013 Govt begins work on 3 more compulsory licences DIPP wants foolproof case on anti-cancer drugs of Roche‚ Bristol-Myers The department of industrial policy and promotion is actively considering the grant of compulsory licences for three new anti-cancer drugs. The department‚ a wing of the commerce ministry‚ which also looks at intellectual property-related issues‚ has sought details regarding prices‚ efficacy levels and
Free Royalties Patent Patent law
from http://www.pharmamanufacturing.com/industrynews/2012/036.html Gassman‚ O.‚ Reepmeyer‚ G.‚ & Von Zedtwitz‚ M Herper‚ M. (2012‚ February 10). The truly staggering cost of inventing new drugs. Retrieved from http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ Highbeam Business‚ 2013 Hoovers. (2013). Pharmaceuticals Manufacturing. Retrieved February 28‚ 2013 from http://ezproxy.una.edu:2204/H/industry360/description.html?industryId=1486 Hoovers
Premium Pharmaceutical industry Pharmacology Generic drug
Khushal Malik – 28 Sharad Singh – 49 PHARMACEUTICAL INDUSTRY – Global Trend • • • • Mainly concentrated in the United States‚ Europe‚ and Japan Developing a drug from discovery to launch took 10 to 12 years. Cost of development of drug is between $500-$800 million. Drugs were strictly controlled by government agencies: o Food and Drug Administration (FDA) – USA‚ o CPMP – Europe o MHW – Japan o DPCO & Indian Patent Act - India • Size of industry : USD 960 billion in 2012. • Few Firms
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
before hand that the FTC opposes agreements that restricted the introduction of generic drugs which could be anti-competitive. Bristol- Myers was hoping that it could have pursued a settlement with Apotex subjected to FTC approval and delay the launch of Apotex generic drug until its patent expire. Bristol-Myers Squibb and Sanofi-Aventis should have attempted to pay Apotex to prevent it from launching the generic drug. It seems that BMS only entered the agreement because they felt that Apotex could
Premium Pharmaceutical industry Generic drug
Ranbaxy Laboratories Limited‚ India’s leading pharmaceutical company‚ announced that it would become a subsidiary of the Japanese drug-manufacturing firm Daiichi Sankyo Co. Ltd. Ranbaxy‚ established in the 1960s by the entrepreneur Bhai Mohan Singh‚ had expanded aggressively over the years and became a global firm with manufacturing operations in 11 countries and it sells drugs in 125 countries. One of the earliest
Premium Pharmaceutical industry Generic drug
Hamied which was registered as public limited company with a capital of Rs. 6 Lakhs. Every year this industry produces drugs worth Rs. 18000 Crores with a profit of 9%. There are 20000 production units in the home countryand the products are exported all over the world at a cheaper price than other international companies. It soon became the top bestselling producers of generic products within the country.Cipla has a flat organisation structure. The firm consists of a large number of educated manpower
Premium Generic drug Pharmaceutical industry
VISION To be preferred provider of quality and affordable healthcare solutions in the region. MISSION To provide our partners truly affordable and quality healthcare solutions • PATIENT To make our products and services available to majority of households. • DOCTORS AND ALLIED PROFESSIONALS To enrich the profession of our partners in the medical community by helping them achieve patient compliance. • TRADE To build lasting‚ productive and value adding partnership by contributing to their
Premium Generic drug Pharmaceutical industry Pharmacology
products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired. In December 2005‚ Ranbaxy’s shares were hit hard by a patent ruling disallowing production of its own version of Pfizer’s cholesterol-cutting drug Lipitor‚ which has annual sales of more than $10 billion.[3] In June 2008‚ Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium‚ the generic version of Lipitor(R)and
Premium Ranbaxy Laboratories Generic drug
companies‚ giving them less of an incentive to innovate. As a result‚ society loses. The paper will challenge this argument by considering the social benefit of allowing patents to expire and giving them less protection‚ through cheaper pricing of generic drugs‚ resulting in a greater number of innovations to society and investment in R&D. I will also discuss the importance of public funding of projects in the R&D phase‚ particularly among small inventors‚ along with the benefit of research done by universities
Premium Generic drug Patent Pharmaceutical industry
government and managed health services providers. In the 1980’s the Merck was very successful in producing 10 major new drugs and had a very healthy pipeline. In later years‚ Merck has entered into joint ventures with many other pharmaceutical companies in order to expand its pipeline. In the last several years Merck has experienced a decline in revue do to several of their exclusive drugs going off-patent. Merck is currently the eighth largest pharmaceutical firm in the world. In 2009‚ Merck plans
Premium Generic drug Pharmaceutical industry Mergers and acquisitions